Published in Int J Radiat Oncol Biol Phys on August 06, 2009
The clinical application of 4D 18F-FDG PET/CT on gross tumor volume delineation for radiotherapy planning in esophageal squamous cell cancer. J Radiat Res (2012) 0.95
Current concepts in F18 FDG PET/CT-based radiation therapy planning for lung cancer. Front Oncol (2012) 0.83
Challenges and opportunities in patient-specific, motion-managed and PET/CT-guided radiation therapy of lung cancer: review and perspective. Clin Transl Med (2012) 0.82
Conventional 3D staging PET/CT in CT simulation for lung cancer: impact of rigid and deformable target volume alignments for radiotherapy treatment planning. Br J Radiol (2011) 0.82
Interobserver delineation variation in lung tumour stereotactic body radiotherapy. Br J Radiol (2012) 0.79
The application of PET-CT to post-mastectomy regional radiation therapy using a deformable image registration. Radiat Oncol (2013) 0.78
The mediastinal staging accuracy of 18F-Fluorodeoxyglycose positron emission tomography/computed tomography in non-small cell lung cancer with variable time intervals to surgery. Ulster Med J (2013) 0.77
Consequences of additional use of contrast-enhanced (18)F-FDG PET/CT in target volume delineation and dose distribution for pancreatic cancer. Br J Radiol (2015) 0.76
Comparison of primary target volumes delineated on four-dimensional CT and 18 F-FDG PET/CT of non-small-cell lung cancer. Radiat Oncol (2014) 0.75
Efficacy of FDG-PET for defining gross tumor volume of head and neck cancer. J Radiat Res (2013) 0.75
The use of PET/CT in radiotherapy planning: contribution of deformable registration. Front Oncol (2013) 0.75
Comparative evaluation of target volumes defined by deformable and rigid registration of diagnostic PET/CT to planning CT in primary esophageal cancer. Medicine (Baltimore) (2017) 0.75
Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials. Front Oncol (2017) 0.75
Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis. Am J Respir Crit Care Med (2014) 3.50
Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer (2009) 3.31
The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. Cancer (2011) 2.29
A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol (2012) 2.09
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol (2012) 2.06
Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies. Int J Radiat Oncol Biol Phys (2010) 1.72
UK audit of left ventricular ejection fraction estimation from equilibrium ECG gated blood pool images. Nucl Med Commun (2005) 1.55
Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles. Sci Rep (2011) 1.50
The state of clinical pharmacy practice in family practice residency programs. Fam Med (2002) 1.36
Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood (2004) 1.34
Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis (2008) 1.32
Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One (2013) 1.29
Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther (2008) 1.27
Nanodosimetric effects of gold nanoparticles in megavoltage radiation therapy. Radiother Oncol (2011) 1.20
Cell type-dependent uptake, localization, and cytotoxicity of 1.9 nm gold nanoparticles. Int J Nanomedicine (2012) 1.12
From personal challenge to technical fix: the risks of depersonalised care. Health Soc Care Community (2011) 0.99
Out-of-field cell survival following exposure to intensity-modulated radiation fields. Int J Radiat Oncol Biol Phys (2011) 0.99
Enteral feeding methods for nutritional management in patients with head and neck cancers being treated with radiotherapy and/or chemotherapy. Cochrane Database Syst Rev (2010) 0.98
Enteral feeding methods for nutritional management in patients with head and neck cancers being treated with radiotherapy and/or chemotherapy. Cochrane Database Syst Rev (2013) 0.98
Bone-targeting radiopharmaceuticals including radium-223. Cancer J (2013) 0.96
Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy. Clin Cancer Res (2012) 0.96
A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study. Eur J Nucl Med Mol Imaging (2002) 0.95
The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv (2010) 0.95
A kinetic-based model of radiation-induced intercellular signalling. PLoS One (2013) 0.89
A study of the biological effects of modulated 6 MV radiation fields. Phys Med Biol (2010) 0.89
DNA damage responses following exposure to modulated radiation fields. PLoS One (2012) 0.88
What is the Role of the Bystander Response in Radionuclide Therapies? Front Oncol (2013) 0.88
Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement. Radiother Oncol (2004) 0.87
18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiotherapy target volume definition in non-small-cell lung cancer: delineation by radiation oncologists vs. joint outlining with a PET radiologist? Int J Radiat Oncol Biol Phys (2010) 0.85
Octavius 4D characterization for flattened and flattening filter free rotational deliveries. Med Phys (2013) 0.83
A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer. J Cancer Surviv (2015) 0.83
Temporal characterization and in vitro comparison of cell survival following the delivery of 3D-conformal, intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT). Phys Med Biol (2011) 0.83
Dose, dose-rate and field size effects on cell survival following exposure to non-uniform radiation fields. Phys Med Biol (2012) 0.83
A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer. Eur J Nucl Med Mol Imaging (2003) 0.83
Neuroendocrine carcinoma arising in soft tissue: three case reports and literature review. World J Surg Oncol (2007) 0.82
Failure to achieve a PSA level <or=1 ng/mL after neoadjuvant LHRHa therapy predicts for lower biochemical control rate and overall survival in localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys (2007) 0.82
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol (2014) 0.82
In-vitro investigation of out-of-field cell survival following the delivery of conformal, intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) plans. Phys Med Biol (2012) 0.81
Narrative research methods in palliative care contexts: two case studies. J Pain Symptom Manage (2008) 0.81
Assessing software upgrades, plan properties and patient geometry using intensity modulated radiation therapy (IMRT) complexity metrics. Med Phys (2011) 0.81
A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). Eur J Nucl Med Mol Imaging (2011) 0.81
Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink. Cancer Causes Control (2013) 0.81
A computational model of cellular response to modulated radiation fields. Int J Radiat Oncol Biol Phys (2012) 0.80
Relative biological effectiveness (RBE) and out-of-field cell survival responses to passive scattering and pencil beam scanning proton beam deliveries. Phys Med Biol (2012) 0.80
Conventional in vivo irradiation procedures are insufficient to accurately determine tumor responses to non-uniform radiation fields. Int J Radiat Biol (2014) 0.80
Use of radionuclides in metastatic prostate cancer: pain relief and beyond. Curr Opin Support Palliat Care (2012) 0.79
Implications of intercellular signaling for radiation therapy: a theoretical dose-planning study. Int J Radiat Oncol Biol Phys (2013) 0.78
Palmar fasciitis: a para-neoplastic phenomenon indicating recurrence of non small cell lung cancer - case report and review of the literature. Int J Rheum Dis (2011) 0.78
The mediastinal staging accuracy of 18F-Fluorodeoxyglycose positron emission tomography/computed tomography in non-small cell lung cancer with variable time intervals to surgery. Ulster Med J (2013) 0.77
Intensity-modulated radiotherapy reduces lung irradiation in patients with carcinoma of the oesophagus. Front Radiat Ther Oncol (2002) 0.77
Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer. Chin J Cancer (2013) 0.77
Cellular signalling effects in high precision radiotherapy. Phys Med Biol (2015) 0.77
Tumor dosimetry on SPECT (186)Re-HEDP scans: variations in the results from the reconstruction methods used. Cancer Biother Radiopharm (2007) 0.76
Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol (2005) 0.75
The quantitative surface analysis of an antioxidant additive in a lubricant oil matrix by desorption electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom (2013) 0.75
Letter to editor. Re: "Effect of concomitant use of pentoxifylline (PTX) and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer". Med Oncol (2007) 0.75
Standardization of scanning for [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol (2009) 0.75
Investigating the influence of respiratory motion on the radiation induced bystander effect in modulated radiotherapy. Phys Med Biol (2013) 0.75
Feasibility of portal dosimetry for flattening filter-free radiotherapy. J Appl Clin Med Phys (2016) 0.75
Development of a novel experimental model to investigate radiobiological implications of respiratory motion in advanced radiotherapy. Phys Med Biol (2012) 0.75
A Monte Carlo analysis technique applied to cerebral perfusion SPECT scans. Nucl Med Commun (2005) 0.75
A novel method for more accurately mapping the surface temperature of ultrasonic transducers. Ultrasound Med Biol (2011) 0.75
A simple model for predicting the signal for a head-mounted transmission chamber system, allowing IMRT in-vivo dosimetry without pretreatment linac time. J Appl Clin Med Phys (2014) 0.75
UK audit of analysis of quantitative parameters from renography data generated using a physical phantom. Nucl Med Commun (2014) 0.75
UK audit of relative lung function measurement from planar radionuclide imaging. Nucl Med Commun (2004) 0.75
A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases. Phys Med Biol (2017) 0.75